Metoclopramide: Uses, Dosage & Side Effects
Antiemetic & Prokinetic Agent — Prevents nausea and vomiting, promotes gastric emptying
Quick Facts About Metoclopramide
Key Takeaways About Metoclopramide
- Dual mechanism of action: Metoclopramide works both centrally (blocking dopamine receptors in the brain's chemoreceptor trigger zone) and peripherally (enhancing upper GI motility), making it effective for both nausea and delayed gastric emptying
- Short-term use only: Treatment should not exceed 5 days in most cases. Do not use for longer than 3 months under any circumstances due to the risk of tardive dyskinesia, a potentially irreversible movement disorder
- Strict dosing interval: You must wait at least 6 hours between doses, even if you vomit after taking a dose. The maximum daily dose is 30 mg or 0.5 mg/kg body weight for adults
- Important drug interactions: Must not be taken with levodopa or dopamine agonists. Can interact with sedatives, morphine derivatives, antipsychotics, and several other drug classes
- Special populations require caution: Children and young adults are at higher risk for involuntary movements (extrapyramidal symptoms). Dose reduction is needed for patients with kidney or liver problems
What Is Metoclopramide and What Is It Used For?
Metoclopramide is an antiemetic (anti-nausea) and prokinetic medication that acts on dopamine receptors in the brain and gastrointestinal tract. It prevents nausea and vomiting by blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and also accelerates gastric emptying by enhancing upper GI motility. It is used to treat nausea and vomiting from various causes, including chemotherapy, radiation therapy, and migraine.
Metoclopramide belongs to the substituted benzamide class of medications and has been in clinical use since the 1960s. It was one of the first prokinetic agents introduced and remains widely prescribed around the world for the management of nausea, vomiting, and gastroparesis. The medication occupies a unique pharmacological position because it provides both antiemetic and gastroprokinetic effects through a single agent.
The drug exerts its antiemetic effect primarily through antagonism of dopamine D2 receptors in the chemoreceptor trigger zone (CTZ), a region in the area postrema of the brainstem that lies outside the blood-brain barrier and plays a central role in triggering the vomiting reflex. At higher doses, metoclopramide also blocks serotonin 5-HT3 receptors, which contributes to its effectiveness against chemotherapy-induced nausea and vomiting (CINV). Its prokinetic activity results from facilitation of acetylcholine release from enteric neurons and direct antagonism of dopamine receptors in the myenteric plexus, leading to increased gastric contractions, raised lower esophageal sphincter tone, and accelerated gastric emptying.
Metoclopramide is available in several dosage forms, including oral tablets, film-coated tablets, and injectable solutions for intravenous or intramuscular administration. The injectable form is typically reserved for hospital settings where rapid onset of action is needed or when oral administration is not possible due to severe vomiting.
Approved Indications
Metoclopramide is approved for the following clinical uses in adults and, in limited circumstances, in children:
- Prevention of delayed chemotherapy-induced nausea and vomiting (CINV): Metoclopramide is used to prevent the nausea and vomiting that can occur in the days following chemotherapy treatment. It is typically given as part of a multi-drug antiemetic regimen for patients receiving moderately to highly emetogenic chemotherapy.
- Prevention of radiation-induced nausea and vomiting: Patients undergoing radiation therapy, particularly to the abdomen, may experience significant nausea. Metoclopramide can help prevent and manage these symptoms.
- Treatment of established nausea and vomiting: The medication is effective for treating nausea and vomiting from various causes, including post-operative nausea, drug-induced nausea, and nausea associated with metabolic conditions.
- Nausea and vomiting associated with migraine: During migraine attacks, gastric stasis (delayed stomach emptying) is common, which can impair the absorption of oral pain medications. Metoclopramide both treats migraine-associated nausea and promotes gastric emptying, thereby enhancing the absorption and effectiveness of co-administered oral analgesics such as paracetamol or NSAIDs.
- Children (ages 1–18 years): In pediatric patients, metoclopramide is used only for the prevention of delayed chemotherapy-induced nausea and vomiting, and only when other antiemetic treatments have failed or are not appropriate.
Metoclopramide acts through multiple mechanisms. Centrally, it blocks dopamine D2 receptors in the chemoreceptor trigger zone (CTZ), preventing signals from reaching the vomiting center in the brainstem. Peripherally, it enhances gastric motility by facilitating acetylcholine release from cholinergic neurons in the gut wall and by blocking inhibitory dopamine receptors in the myenteric plexus. The result is coordinated gastric contractions, increased lower esophageal sphincter pressure, and accelerated movement of food from the stomach to the small intestine. At higher doses, it also antagonizes 5-HT3 serotonin receptors, which is particularly relevant for its antiemetic effect in chemotherapy settings.
What Should You Know Before Taking Metoclopramide?
Before taking metoclopramide, you must be aware of several important contraindications and warnings. The medication must not be used in patients with gastrointestinal bleeding or obstruction, pheochromocytoma, epilepsy, Parkinson's disease, or a history of tardive dyskinesia. Treatment duration should be as short as possible, generally not exceeding 5 days.
Metoclopramide is a potent dopamine antagonist with significant effects on both the central nervous system and the gastrointestinal tract. While it is effective for its approved indications, its pharmacological profile means it carries specific risks that patients and prescribers must be aware of. Understanding these precautions is essential for safe use.
Contraindications
You must not take metoclopramide if any of the following apply:
- Allergy to metoclopramide: If you have a known hypersensitivity to metoclopramide or any of the inactive ingredients in the formulation (such as lactose monohydrate, magnesium stearate, or corn starch).
- Gastrointestinal bleeding, obstruction, or perforation: Metoclopramide increases gastric motility and could worsen these conditions, potentially leading to a medical emergency.
- Pheochromocytoma (confirmed or suspected): This rare adrenal gland tumor produces catecholamines. Metoclopramide can trigger a dangerous hypertensive crisis in patients with pheochromocytoma.
- History of tardive dyskinesia: If you have ever experienced tardive dyskinesia (involuntary repetitive movements) from any medication, metoclopramide must not be used, as it can trigger or worsen this condition.
- Epilepsy: Metoclopramide can increase the frequency and severity of seizures and is contraindicated in patients with epilepsy.
- Parkinson's disease: Because metoclopramide blocks dopamine receptors, it directly antagonizes the dopaminergic pathways that are already deficient in Parkinson's disease and will worsen symptoms.
- Concurrent use with levodopa or dopamine agonists: These medications have opposing mechanisms of action. Metoclopramide blocks dopamine receptors while levodopa and dopamine agonists stimulate them, creating a pharmacological conflict.
- History of methemoglobinemia or NADH cytochrome-b5 deficiency: Metoclopramide can cause or worsen methemoglobinemia, a condition where hemoglobin is unable to carry oxygen effectively.
- Children under 1 year of age: Due to the significantly increased risk of extrapyramidal reactions in very young children.
Warnings and Precautions
Speak with your healthcare provider before taking metoclopramide if any of the following conditions apply to you. These situations require careful medical assessment and may necessitate dose adjustments or enhanced monitoring:
- Involuntary movements of the face, tongue, jaw, or limbs (may indicate tardive dyskinesia or acute dystonia)
- High fever, muscle rigidity, altered consciousness, rapid heartbeat, unstable blood pressure, excessive sweating (signs of neuroleptic malignant syndrome — a rare but life-threatening emergency)
- Itching, skin rash, swelling of face, lips, throat, or tongue, difficulty breathing (signs of a severe allergic reaction)
- Unusual darkening of the skin or lips (may indicate methemoglobinemia)
The following situations require particular caution when using metoclopramide:
- Heart rhythm abnormalities: Metoclopramide can prolong the QT interval on an ECG. Inform your doctor if you have a history of QT prolongation, other heart rhythm problems, or electrolyte imbalances (particularly low potassium, sodium, or magnesium).
- Neurological conditions: Patients with brain or spinal cord disorders should be closely monitored, as metoclopramide crosses the blood-brain barrier and can affect neurological function.
- Kidney or liver problems: Metoclopramide is eliminated through both hepatic metabolism and renal excretion. Patients with impaired kidney or liver function may require dose reductions to avoid drug accumulation and increased risk of side effects.
- Elderly patients: Older adults are more susceptible to the neurological side effects of metoclopramide, including tardive dyskinesia and extrapyramidal symptoms. The lowest effective dose should be used for the shortest possible duration.
- Children and adolescents: Extrapyramidal reactions (involuntary movements) occur more frequently in young patients. These typically appear early in treatment and can occur even after a single dose. They resolve after appropriate treatment and discontinuation of the drug.
You must wait at least 6 hours between each dose of metoclopramide, even if you vomit after taking a dose. Taking doses too close together significantly increases the risk of overdose and neurological side effects. Do not take a replacement dose if you vomit shortly after administration.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare provider before taking metoclopramide. The available clinical data from a large number of exposed pregnancies has not indicated an increased risk of malformations or fetal toxicity. However, as with all medications during pregnancy, metoclopramide should only be used when the potential benefit justifies the potential risk, and the decision should be made by your doctor.
Metoclopramide passes into breast milk and may affect the nursing infant. Because of the potential for serious adverse reactions in breastfed infants, including extrapyramidal effects, metoclopramide is not recommended during breastfeeding. If treatment is considered necessary, breastfeeding should be discontinued during therapy.
Driving and Operating Machinery
Metoclopramide can cause drowsiness, dizziness, and involuntary movements (dyskinesia and dystonia) that may affect vision and coordination. These effects can significantly impair your ability to drive, operate machinery, or perform tasks requiring alertness and fine motor control. You should not drive or engage in potentially hazardous activities until you know how metoclopramide affects you personally. The sedative effects may be enhanced by concurrent use of alcohol or other CNS depressants.
How Does Metoclopramide Interact with Other Drugs?
Metoclopramide has clinically significant interactions with several drug classes. It must not be used with levodopa or dopamine agonists. Because it increases gastrointestinal motility, it can alter the absorption of many orally administered drugs. It can also enhance the sedative effects of alcohol, benzodiazepines, and opioids. Always inform your doctor about all medications you are taking.
Drug interactions with metoclopramide occur through several mechanisms. As a dopamine receptor antagonist, it directly opposes the effects of dopaminergic medications. By accelerating gastric emptying and intestinal transit, it can alter the rate and extent of absorption of other oral drugs. Additionally, metoclopramide can potentiate the central nervous system effects of sedative drugs and alcohol. Understanding these interactions is essential for safe prescribing and use.
Major Interactions
The following interactions are considered clinically significant and may require avoidance of the combination, dose adjustment, or enhanced monitoring:
| Drug | Interaction | Clinical Significance |
|---|---|---|
| Levodopa / Dopamine agonists | Mutual antagonism — metoclopramide blocks the dopamine receptors that levodopa activates | Contraindicated — do not use together |
| Antipsychotics / Neuroleptics | Additive dopamine blockade increases risk of extrapyramidal symptoms and neuroleptic malignant syndrome | Avoid combination; increased neurological risk |
| Morphine / Opioid analgesics | Additive CNS depression; opioids also slow GI motility, opposing metoclopramide's prokinetic effect | Monitor for excessive sedation; dose adjustments may be needed |
| Anticholinergic drugs | Anticholinergics oppose metoclopramide's prokinetic effect on the GI tract | Reduced metoclopramide effectiveness; avoid if possible |
| Serotonergic drugs (SSRIs) | Combined serotonergic activity may increase risk of serotonin syndrome at high doses | Monitor for symptoms of serotonin syndrome |
| QT-prolonging drugs | Additive QT prolongation increases risk of cardiac arrhythmias | Avoid combination; ECG monitoring if unavoidable |
Other Notable Interactions
The following interactions require awareness. Your doctor should be informed if you are taking any of these medications alongside metoclopramide:
| Drug | Effect | Action Required |
|---|---|---|
| Digoxin | Reduced digoxin absorption due to accelerated GI transit | Monitor digoxin levels; dose adjustment may be needed |
| Ciclosporin | Increased ciclosporin absorption and bioavailability | Monitor ciclosporin levels closely |
| Fluoxetine / Paroxetine | CYP2D6 inhibition may increase metoclopramide exposure | Monitor for increased side effects |
| Rifampicin | CYP2D6 induction may reduce metoclopramide blood levels | May need higher metoclopramide dose |
| Mivacurium / Suxamethonium | Metoclopramide may prolong the neuromuscular blocking effect | Inform anesthetist; monitor neuromuscular function |
| Sedatives / Benzodiazepines | Enhanced sedation and CNS depression | Monitor for excessive drowsiness |
| Alcohol | Enhanced sedative effect of metoclopramide | Avoid alcohol during treatment |
Because metoclopramide accelerates gastric emptying and intestinal transit, it can affect the absorption of other orally administered medications. Drugs that are normally absorbed in the stomach may have reduced absorption, while drugs absorbed in the small intestine may be absorbed more quickly. If you take other medications, discuss timing with your doctor or pharmacist to ensure optimal absorption of all your treatments.
What Is the Correct Dosage of Metoclopramide?
The recommended adult dose is 10 mg up to three times daily, with a maximum daily dose of 30 mg or 0.5 mg/kg body weight. You must wait at least 6 hours between doses. The maximum recommended treatment duration is 5 days. Dose reductions are necessary for patients with kidney or liver impairment.
Metoclopramide dosing must be carefully individualized and kept to the lowest effective dose for the shortest possible duration. Exceeding the recommended dose or treatment duration significantly increases the risk of neurological side effects, particularly tardive dyskinesia and extrapyramidal symptoms. The following guidelines represent standard dosing recommendations based on international prescribing information.
Adults
| Indication | Dose | Duration |
|---|---|---|
| Nausea and vomiting (general) | 10 mg up to 3 times daily | Up to 5 days |
| Delayed chemotherapy-induced nausea | 10 mg up to 3 times daily | Up to 5 days per cycle |
| Radiation-induced nausea | 10 mg up to 3 times daily | Up to 5 days |
| Migraine-associated nausea | 10 mg single dose (with analgesic) | Single dose; may repeat after 6 hours |
Important Dosing Rules for Adults
- Maximum single dose: 10 mg
- Maximum daily dose: 30 mg or 0.5 mg/kg body weight (whichever is lower)
- Minimum interval between doses: 6 hours
- Maximum treatment duration: 5 days
- Administration: Swallow tablets whole with a glass of water
Children (Ages 1–18 Years)
Metoclopramide is only approved in children for the prevention of delayed chemotherapy-induced nausea and vomiting when other treatments have failed or cannot be used. The recommended dose is weight-based:
| Age | Body Weight | Dose | Frequency |
|---|---|---|---|
| 1–3 years | 10–14 kg | 1 mg | Up to 3 times daily |
| 3–5 years | 15–19 kg | 2 mg | Up to 3 times daily |
| 5–9 years | 20–29 kg | 2.5 mg | Up to 3 times daily |
| 9–18 years | 30–60 kg | 5 mg | Up to 3 times daily |
| 15–18 years | Over 60 kg | 10 mg | Up to 3 times daily |
The recommended pediatric dose is 0.1 to 0.15 mg/kg body weight, administered up to three times daily by mouth. The maximum daily dose is 0.5 mg/kg body weight. Treatment should not exceed 5 days. Metoclopramide tablets are not suitable for children weighing less than 30 kg; liquid formulations are more appropriate for this group. Metoclopramide must not be used in children under 1 year of age.
Elderly Patients
Dose reduction may be necessary in elderly patients, depending on kidney function, liver function, and overall clinical status. Elderly patients are at increased risk for tardive dyskinesia and other movement disorders with metoclopramide. The lowest effective dose should be used for the shortest possible duration, and patients should be monitored closely for neurological side effects.
Patients with Kidney Problems
Metoclopramide is partially excreted by the kidneys. In patients with moderate to severe renal impairment, the dose should be reduced to prevent accumulation and increased risk of side effects. Your doctor will determine the appropriate dose based on your kidney function test results (creatinine clearance).
Patients with Liver Problems
In patients with severe liver impairment, the dose should be reduced because the liver plays a role in metabolizing metoclopramide. Impaired hepatic function leads to slower drug elimination and potentially higher blood levels.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to compensate for a missed one. Always maintain the minimum 6-hour interval between doses.
Overdose
If you suspect an overdose of metoclopramide, contact your local poison control center or seek emergency medical attention immediately. Symptoms of overdose may include involuntary movements (extrapyramidal disorders), drowsiness, reduced level of consciousness, confusion, hallucinations, and cardiac problems including QT prolongation and cardiac arrest. Treatment is supportive and symptomatic. Extrapyramidal symptoms may be treated with anticholinergic agents (such as benztropine or biperiden). Metoclopramide is not effectively removed by hemodialysis.
What Are the Side Effects of Metoclopramide?
Like all medications, metoclopramide can cause side effects. The most common is drowsiness, affecting more than 1 in 10 users. Movement disorders (extrapyramidal symptoms) are an important concern, particularly with higher doses, prolonged use, or in children and young adults. Serious but rare side effects include neuroleptic malignant syndrome and tardive dyskinesia. Seek immediate medical attention if you experience involuntary movements, high fever with muscle rigidity, or signs of a severe allergic reaction.
The side effect profile of metoclopramide is largely related to its dopamine-blocking activity in the central nervous system. Most side effects are dose-dependent and resolve when the medication is discontinued. However, some neurological effects, particularly tardive dyskinesia, may be irreversible, which is why treatment duration must be kept as short as possible. The following side effects have been reported and are classified by frequency according to standard medical convention.
- Involuntary movements of the head, neck, face, or body (extrapyramidal reactions) — especially common in children and with higher doses
- High fever, muscle rigidity, rapid heartbeat, excessive sweating, salivation, altered consciousness (neuroleptic malignant syndrome — a life-threatening emergency)
- Itching, rash, swelling of face/lips/throat/tongue, difficulty breathing, rapid heartbeat, dizziness, fainting (severe allergic reaction/anaphylaxis)
Very Common Side Effects
- Drowsiness and somnolence
Common Side Effects
- Depression
- Extrapyramidal symptoms: involuntary movements, tics, tremor, muscle stiffness, rigidity
- Parkinson-like symptoms (tremor, rigidity, bradykinesia)
- Restlessness (akathisia)
- Low blood pressure (hypotension), especially with intravenous administration
- Diarrhea
- Weakness and fatigue (asthenia)
Uncommon Side Effects
- Elevated prolactin levels (may cause breast milk production in non-breastfeeding women and men)
- Irregular menstrual periods
- Hallucinations
- Reduced level of consciousness
- Slow heart rate (bradycardia), especially with intravenous administration
- Allergic reactions
- Visual disturbances and involuntary eye movements
Rare Side Effects
- Confusion
- Seizures (particularly in patients with epilepsy)
Frequency Not Known
- Methemoglobinemia (abnormal blood pigment levels, may cause skin discoloration)
- Gynecomastia (abnormal breast tissue development in males)
- Tardive dyskinesia (involuntary muscle spasms after prolonged use, potentially irreversible, especially in elderly)
- Neuroleptic malignant syndrome (high fever, rigidity, sweating, altered consciousness)
- ECG changes, QT prolongation
- Cardiac arrest (particularly with intravenous administration)
- Shock (severe drop in blood pressure, especially with IV use)
- Syncope (fainting, especially with IV use)
- Severe hypertension in patients with pheochromocytoma
- Suicidal thoughts
Extrapyramidal Symptoms — Key Information
Extrapyramidal symptoms (EPS) are among the most important side effects of metoclopramide. These involuntary movement disorders result from dopamine receptor blockade in the basal ganglia of the brain. They are more common in children, adolescents, and young adults, and the risk increases with higher doses and longer treatment durations.
EPS can include acute dystonia (sustained muscle contractions causing twisting postures, particularly of the head, neck, and tongue), akathisia (a distressing sensation of inner restlessness with an inability to sit still), drug-induced parkinsonism (tremor, rigidity, and slowness of movement), and tardive dyskinesia (repetitive, involuntary movements, typically of the face and tongue, that may develop after prolonged use).
Acute dystonic reactions typically occur within the first 24–48 hours of treatment and may occur after a single dose. They are usually reversible and respond well to treatment with anticholinergic medications such as benztropine or biperiden. Tardive dyskinesia, however, may be irreversible, which is the primary reason treatment with metoclopramide must not exceed the recommended duration.
If you experience any side effects, including those not listed above, report them to your healthcare provider. You can also report side effects directly to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA in the European Union). Reporting helps ensure the ongoing safety monitoring of medications.
How Should You Store Metoclopramide?
Store metoclopramide at or below 30°C (86°F) in its original packaging. Keep out of sight and reach of children. Do not use after the expiration date printed on the packaging.
Proper storage of metoclopramide ensures the medication remains effective and safe throughout its shelf life. The following storage conditions apply to the tablet formulation:
- Temperature: Store at or below 30°C (86°F). Do not refrigerate or freeze tablets.
- Packaging: Keep the tablets in their original blister pack to protect from moisture and light.
- Children: Store out of sight and reach of children at all times.
- Expiration: Do not use metoclopramide after the expiration date printed on the blister or carton. The expiration date refers to the last day of the indicated month.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired medications to a pharmacy for proper disposal to protect the environment.
Injectable solutions of metoclopramide have specific storage requirements that differ from the oral tablets. Hospital pharmacies and healthcare providers follow dedicated protocols for storage and handling of injectable formulations.
What Does Metoclopramide Contain?
Metoclopramide tablets contain the active substance metoclopramide hydrochloride (10 mg per tablet). Inactive ingredients include lactose monohydrate, pregelatinized starch, corn starch, colloidal anhydrous silica, and magnesium stearate. The tablet is white to off-white, round, biconvex, and scored for easy division.
Understanding the full composition of your medication helps identify potential allergens or intolerances. Exact formulations may vary between manufacturers.
Active Ingredient
The active substance is metoclopramide hydrochloride. Each tablet contains 10 mg of metoclopramide hydrochloride. The injectable solution contains 5 mg/ml of metoclopramide hydrochloride.
Common Excipients (Tablets)
The following inactive ingredients are commonly found in metoclopramide tablet formulations. Exact compositions vary by manufacturer:
- Lactose monohydrate (filler/diluent)
- Pregelatinized starch (binder/disintegrant)
- Corn starch (filler/disintegrant)
- Colloidal anhydrous silica (glidant)
- Magnesium stearate (lubricant)
Lactose content: Metoclopramide tablets typically contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, consult your healthcare provider before taking this medication.
Tablet Appearance
Standard metoclopramide 10 mg tablets are white to off-white, round, biconvex tablets with a score line on one side that allows the tablet to be divided into two equal halves. Markings vary by manufacturer. Available pack sizes typically include 20, 24, 28, 30, 40, 50, 60, 84, 100, or 500 tablets in PVC/PVDC/aluminum blister packs.
Frequently Asked Questions About Metoclopramide
Medical References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official drug regulatory documentation. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
- European Medicines Agency (EMA). "Metoclopramide-containing medicines — Referral under Article 31." EMA EMA review of metoclopramide safety, leading to restricted use and maximum 5-day treatment duration.
- U.S. Food and Drug Administration (FDA). "Metoclopramide — Prescribing Information and Black Box Warning." FDA FDA-required black box warning regarding risk of tardive dyskinesia with prolonged use.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines — 23rd list." WHO Essential Medicines Metoclopramide is listed as a WHO essential medicine for gastrointestinal disorders.
- British National Formulary (BNF). "Metoclopramide hydrochloride: Indications, dose, contraindications, side effects, interactions." BNF / NICE Comprehensive UK drug monograph including dosing, interactions, and monitoring guidance.
- Rao AS, Camilleri M (2010). "Review article: metoclopramide and tardive dyskinesia." Alimentary Pharmacology & Therapeutics. 31(1):11–19. doi:10.1111/j.1365-2036.2009.04189.x Comprehensive review of metoclopramide-induced tardive dyskinesia risk factors and prevention.
- Hesketh PJ, et al. (2020). "Antiemetics: ASCO Guideline Update." Journal of Clinical Oncology. 38(24):2782–2797. doi:10.1200/JCO.20.01296 ASCO guideline on prevention and management of chemotherapy-induced nausea and vomiting, including the role of metoclopramide.
- Roila F, et al. (2016). "2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting." Annals of Oncology. 27(suppl 5):v119–v133. doi:10.1093/annonc/mdw270 International consensus guidelines on antiemetic use in cancer treatment.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in gastroenterology, pharmacology, and clinical medicine
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team includes:
Gastroenterology Specialists
Licensed physicians specializing in gastroenterology and hepatology, with documented experience in gastrointestinal motility disorders and antiemetic pharmacotherapy.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of drug interactions, pharmacokinetics, and evidence-based prescribing.
Researchers
Academic researchers with published peer-reviewed articles on antiemetic therapy, prokinetic agents, and gastrointestinal pharmacology.
Medical Review
Independent review panel that verifies all content against international medical guidelines and current research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in gastroenterology, pharmacology, internal medicine, and clinical research.